Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17525722 | 0.74 | MEN1 (0.36) | MEN1POLBKMT2AALDH1A1CA1 | |
| SCHEMBL854453 | 0.72 | MEN1 (0.37) | MEN1POLBKMT2ACA1CA2 | |
| SCHEMBL17525749 | 0.71 | TNKS (0.37) | MEN1POLBKMT2AHTR1A | |
| SCHEMBL17525744 | 0.71 | MEN1 (0.36) | MEN1POLBKMT2ACA1CA2 | |
| SCHEMBL17525608 | 0.71 | CA1 (0.39) | MEN1POLBKMT2AALDH1A1CA1 | |
| SCHEMBL17525759 | 0.71 | MEN1 (0.36) | MEN1POLBKMT2ACA1CA2 | |
| SCHEMBL17525782 | 0.69 | HRH3 (0.50) | — | |
| SCHEMBL20827820 | 0.69 | TSHR (0.55) | MEN1POLBKMT2AALDH1A1 | |
| SCHEMBL17525761 | 0.68 | CA1 (0.41) | MEN1POLBKMT2ATDP1ALDH1A1 | |
| SCHEMBL17525630 | 0.68 | MEN1 (0.36) | MEN1POLBKMT2ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3722290-B1 | GLUTARIMIDE DERIVATIVE, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING THE GLUTARIMIDE DERIVATIVE | VALENTA INTELLEKT LTD (RU) | 2023-06-21 | — | — | EP | disclosed |
| EP-3725785-A1 | GLUTARIMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING GLUTARIMIDE DERIVATIVES | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2020-10-21 | — | — | EP | disclosed |
| EP-3722290-A1 | GLUTARIMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING GLUTARIMIDE DERIVATIVES | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2020-10-14 | — | — | EP | disclosed |
| US-10377739-B2 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” (RU) | 2019-08-13 | — | — | US | disclosed |
| US-20190084961-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2019-03-21 | — | — | US | disclosed |
| US-10196377-B2 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” (RU) | 2019-02-05 | — | — | US | disclosed |
| US-20180022728-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2018-01-25 | — | — | US | disclosed |
| US-20180022728-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2018-01-25 | — | — | US | disclosed |
| US-20180016255-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2018-01-18 | — | — | US | disclosed |
| US-20180016254-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2018-01-18 | — | — | US | disclosed |
| US-20180016254-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2018-01-18 | — | — | US | disclosed |
| US-20180016255-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2018-01-18 | — | — | US | disclosed |
| US-20180016256-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2018-01-18 | — | — | US | disclosed |
| US-20180016256-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2018-01-18 | — | — | US | disclosed |
| US-20180016257-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2018-01-18 | — | — | US | disclosed |
| US-20180016257-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2018-01-18 | — | — | US | disclosed |
| US-20180016253-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES" (RU) | 2018-01-18 | — | — | US | disclosed |
| US-9815814-B2 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” (RU) | 2017-11-14 | — | — | US | disclosed |
| US-9815814-B2 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” (RU) | 2017-11-14 | — | — | US | disclosed |
| EP-2985282-A1 | GLUTARIMIDE DERIVATIVES, USE THEREOF, PHARMACEUTICAL COMPOSITION BASED THEREON AND METHODS FOR PRODUCING GLUTARIMIDE DERIVATIVES | Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises" (RU) | 2016-02-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377739-B2 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | GCDH, GLS, HADH | MEN1 1963/4885POLB 2372/4885KMT2A 2520/4885 |
| US-20180022728-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | GCDH, GLS, HADH | MEN1 2009/4885POLB 2180/4885KMT2A 2594/4885 |
| US-20180016256-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | GCDH, GOT2, GLS | MEN1 2348/4885POLB 2322/4885KMT2A 2402/4885 |
| US-10196377-B2 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives | GCDH, GLS, HADH | MEN1 1963/4885POLB 2372/4885KMT2A 2520/4885 |
| US-20180016255-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | GCDH, NOTUM, CYP11B2 | MEN1 3780/4885POLB 2923/4885KMT2A 2144/4885 |
| US-20190084961-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | GCDH, GLS, HADH | MEN1 1963/4885POLB 2372/4885KMT2A 2520/4885 |
| US-20180016254-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | GCDH, HADH, GOT2 | MEN1 2112/4885POLB 2370/4885KMT2A 2526/4885 |
| US-20180016253-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | GCDH, GLS, HADH | MEN1 2123/4885POLB 2758/4885KMT2A 2797/4885 |
| US-20180016257-A1 | Glutarimide Derivatives, Use Thereof, Pharmaceutical Composition Based Thereon and Methods for Producing Glutarimide Derivatives | GCDH, HADH, OGDH | MEN1 1324/4885POLB 2275/4885KMT2A 2208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.